Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Home
ATG-201
#
ATG-201
About 2 search results
Sort by Date
Business
PR Newswire
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
SHANGHAI and HONG KONG
PR Newswire
2026-08-25 08:30
Antengene
ATG-201
autoimmune diseases
Business
PR Newswire
Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
SHANGHAI and HONG KONG
PR Newswire
2026-06-10 09:00
Antengene
ATG-201
CD19 x CD3